HealthQuill HIV Prevention
China’s WuXi Biologics, a clinical research organization, has granted global rights to US-based Candid Therapeutics to use the company’s synthetic antibody to fight cancer for an upfront payment of $925 million.
Pharma

Gilead’s once-yearly lenacapavir shot for HIV prevention shows strong promise

HQ Team March 12, 2025: In a significant development for HIV prevention, Gilead Sciences has unveiled promising data from its Phase 1 study.

Read More
The National Instituted of Health, US, has started a mid-stage clinical trial to examine the safety and acceptability of a rectal microbicide douche containing the antiretroviral drug tenofovir to prevent HIV infection spread among men.
Drugs Health Pharma

Mid-stage trial of a rectal microbicide for HIV prevention in the US begins 

HQ Team November 3, 2024: The National Instituted of Health, US, has started a mid-stage clinical trial to examine the safety and acceptability.

Read More
Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a secondary goal of a ‘high’ viral suppression rate in adults.
Drugs Health Pharma

Gilead, Merck’s HIV experimental drug scores ‘high’ on viral suppression

Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a.

Read More
GSK Plc announced that its subsidiary ViiV Healthcare got a green light from the European Commission for the company’s HIV prevention medicine.
Drugs Health Pharma

GSK Plc gets EU approval for HIV prevention drug Apretude

GSK Plc announced that its subsidiary ViiV Healthcare got a green light from the European Commission for the company’s HIV prevention medicine.

Read More